Altimmune (ALT) – Globe Newswire
-
Alternus Clean Energy, Inc. Announces Closing of $2.16 Million Private Placement of Convertible Notes and Warrants
-
Alternus Clean Energy, Inc. Reports FY 2023 Financial Results
-
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
-
Alternus Clean Energy Celebrates Activation of Omohundro Solar Project at Ceremony with Mayor of Nashville, TN
-
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
-
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
-
Clean Earth and Alternus Energy Announce Continuation of Business Combination Close Process
-
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
-
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
-
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
-
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
-
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
-
Altimmune to Participate at Two Upcoming Investor Conferences
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
-
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
-
Altimmune to Participate at Two Upcoming Investor Conferences
-
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
-
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
-
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
-
Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
-
Altimmune to Participate at Two Upcoming Investor Conferences
-
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
-
Altimmune to Participate at Two Upcoming Investor Conferences
-
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
-
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
-
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
-
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
-
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
-
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
-
Altimmune Appoints Raymond Jordt as Chief Business Officer
-
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
-
Altimmune to Participate at Two Upcoming Investor Conferences
-
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
-
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
-
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
-
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
-
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
-
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
-
Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
-
Altimmune to Participate at Two Upcoming Investor Conferences
-
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
-
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
-
Altimmune to Present at Upcoming Investor Conferences
-
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
-
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Back to ALT Stock Lookup
